SCHEMBL9305499

SCHEMBL9305499

O=C(O)[C@H]1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5026802 1.00 NOS2 (0.43)
SCHEMBL8086969 1.00
SCHEMBL15877835 1.00 NOS2 (0.43)
SCHEMBL26781597 1.00 NOS2 (0.43)
SCHEMBL7381082 1.00 NOS2 (0.43)
SCHEMBL353811 1.00
Water SCHEMBL29376299 0.98 NOS2 (0.41)
SCHEMBL3257162 0.98 NOS2 (0.41)
SCHEMBL239908 0.92
SCHEMBL92737 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103559-B1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2026-03-04 EP disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 US disclosed
US-12516067-B2 Antagonists of the muscarinic acetylcholine receptor M4 VANDERBILT UNIVERSITY (US) 2026-01-06 US disclosed
US-12473304-B2 Heterocyclic PAD4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-18 US disclosed
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
US-20250145595-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNITED STATES GOVERNMENT 2025-05-08 US disclosed
CN-115348961-B Heterocyclic PAD4 inhibitors 百时美施贵宝公司 2025-03-04 CN disclosed
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
EP-4444728-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 EP disclosed
CN-114502158-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2022-05-13 CN disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
WO-2022051582-A1 SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF NodThera Limited (GB) 2022-03-10 WO disclosed
WO-2022036177-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2022-02-17 WO disclosed
WO-2021216949-A1 CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2021-10-28 WO disclosed
WO-2021216951-A1 CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2021-10-28 WO disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
WO-2021119265-A1 ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2021-06-17 WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
US-5334730-A Amidation with an 2-aminocarboxylic acid ester, cleavage the amide bond, solvent extraction to isolate CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1994-08-02 US disclosed